Argent BioPharma Limited (ASX:RGT) is an ASX-listed revenue-generating, clinical-stage biopharmaceutical company focused on the development and commercialisation of nano-engineered therapeutics targeting neurological and immune-mediated disorders. Its lead Assets are CannEpil®, a cannabinoid-based treatment for drug-resistant epilepsy, and CimetrA®, targeting inflammatory conditions. The company leverages proprietary nano-delivery technology designed to optimise bioavailability and tissue penetration.

Recent Developments

Argent BioPharma reported a consolidated net loss of $7,710,158 for the year ended 30 June 2026, a 57 percent improvement on the $17,844,295 loss in FY25. Administrative expenses decreased 43 percent to $6.9 million as the non-recurring costs associated with the prior year's Capital Markets and listing activities were not repeated. A major post-period milestone was the entry into a binding transaction framework with Splash Beverage Group (NYSE American: SBEV) for the exclusive global development and commercialisation of CannEpil®. Under the deal, US$5.5 million in secured convertible notes owed to Mercer Street Global Opportunity Fund are to be forgiven — eliminating the company's principal secured Debt without diluting Argent shareholders — while Argent retains 100 percent ownership of the CannEpil® IP, a 15 percent Royalty on net revenues, and its EU-GMP Manufacturing arrangement. During FY26, Argent completed its largest CannEpil® commercial shipment — 1,000 units to Ireland — with an approximate reimbursed retail value of A$783,000. CannPal Animal Therapeutics' Phase 2C study for CPAT-01 in canine osteoarthritis pain met its primary endpoint. A U.S. provisional Patent for NanoBodies was filed, and EU-GMP cannabinoid API Supply commenced to University Medical Centre Ljubljana in Slovenia.

Sector Context

The medical cannabis and nano-delivery therapeutics space continues to attract commercial interest in Europe and increasingly in the United States. The global market for drug-resistant epilepsy treatments is substantial and underserved, with Lennox-Gastaut Syndrome and Dravet Syndrome representing significant unmet needs that CannEpil® targets. The veterinary cannabinoid market is also growing rapidly, providing CannPal with a near-term commercial pathway.

Risk and Uncertainty

Revenue remains very modest at $161,187, and the company is dependent on the execution of the CannEpil®-SBEV licensing agreement and further capital raises to fund operations. Default Risk on convertible note obligations remains a disclosure item. The conversion of the SBEV deal from a binding framework into a fully executed agreement is a critical step, and any delays could affect the Balance Sheet improvement described at announcement.

Catalysts to Watch

Full execution of the Splash Beverage Group licensing agreement for CannEpil® and forgiveness of the Mercer convertible debt is the most material near-term catalyst. Advancement of CannPal's CPAT-01 toward Phase 3 and any Partnership announcement for that asset would also be significant. Growth in CannEpil® Ireland shipments and new European hospital or country approvals for EU-GMP API supply represent ongoing commercial indicators.

Argent BioPharma has materially reduced its operating losses, secured a potentially transformative licensing deal for its lead asset, and added pipeline breadth through CannPal and NanoBodies — positioning the company more durably heading into FY27.